Global Academy of Women's Cancer

Startseite
Deutschland
Neuenhagen
Global Academy of Women's Cancer

Kontaktinformationen, Karte und Wegbeschreibungen, Kontaktformulare, Öffnungszeiten, Dienstleistungen, Bewertungen, Fotos, Videos und Ankündigungen von Global Academy of Women's Cancer, Onkologe, Friedenstraße 58, Neuenhagen.

The Global Academy of Women´s Cancer was initiated by Andreas du Bois, Jonathan Ledermann, Sherko Kümmel and Peter Schmid, to offer a unique global training concept, with key opinion leaders in the fields of gynaecological oncology and breast cancer.

16/04/2026

Prof. Dr. Yesim Eralp (.dr.yesimeralp ) from Istanbul Acıbadem University reflects on the inspiring discussions surrounding the treatment of both metastatic and early-stage breast cancer.

• Dynamic KI-67 Response: Prof. Eralp highlights how monitoring this response in luminal breast cancer patients can potentially help spare them from chemotherapy if they respond well to endocrine therapy.

• Advancing Metastatic Care: Yesterday’s sessions explored the future of endocrine therapy, focusing on the impact of new SERDs and innovative treatment combinations.
The goal? Perfect invasive disease-free survival and more personalized care for every patient. 🩺✨

Stay tuned for more expert insights as we continue to push the boundaries of women’s cancer treatment!

10/04/2026

Prof. Dr. Nadia Harbeck, Director of the Breast Center at LMU University Hospital, shares key takeaways from the session on HR-positive metastatic breast cancer at the Global Academy of Women’s Cancer in Istanbul.

The discussion centered on the rapidly advancing therapeutic landscape and the clinical necessity of personalized treatment strategies:

• Prof. Harbeck underscores the importance of testing for ESR1 and PIK3CA mutations, noting that resistance can emerge dynamically during treatment.

• The Role of Liquid Biopsies: Utilizing liquid biopsies after each line of therapy is vital to identifying new mutations and adapting patient care in real-time.

• The Shift in Standard of Care: A look at how Antibody-Drug Conjugates (ADCs), specifically T-DXd, are increasingly replacing traditional chemotherapy in HER2-low and ultra-low disease settings.

Integrating these insights into clinical practice is fundamental to overcoming endocrine resistance and improving long-term patient outcomes. We thank Prof. Harbeck for her expertise and contribution to our mission.

Explore the full congress summary and upcoming initiatives:
🔗 global-academy-of-womens-cancer.org

26/03/2026

We are continuing our GAWC 2026 Takeaways series directly from Istanbul! In this highlight, we sit down with Prof. Dr. Erhan Gökmen, Medical Oncologist from Izmir, Turkey, to discuss the evolving landscape of breast cancer care.

Prof. Dr. Gökmen shares his insights from our panel on endocrine therapy for early breast cancer patients. A key highlight for him was the discussion surrounding:
• Dynamic Ki-67 Monitoring: Gaining new perspectives from recent German data.
• Clinical Strategy: Integrating these monitoring techniques more frequently into future patient care.

At the Global Academy of Women’s Cancer, our mission is to translate cutting-edge science into practical, everyday clinical recommendations. We are thrilled to provide a platform where experts like Prof. Dr. Gökmen can exchange practice-changing ideas.

17/03/2026

We are pleased to share key insights from the Global Academy of Women’s Cancer Meeting 2026 in Istanbul, featuring Prof. Dr. Sherko Kuemmel, Director of the Interdisciplinary Women’s Cancer Center at Kliniken Essen-Mitte (KEM), Germany.

Prof. Kuemmel discusses the impact of the inaugural panel discussions at GAWC, which fostered a high-level exchange on the complexities of treating metastatic HR-positive disease.

The session highlighted the value of interdisciplinary dialogue, providing a platform for experts to debate diverse opinions and therapeutic options to ultimately enhance patient outcomes in gynecologic oncology.

👉 Follow us for more.

06/03/2026

We are pleased to feature Dr. Roula Ammar Almoufti, Consultant Medical Oncologist at the King Faisal Specialist Hospital and Research Centre in Jeddah, as she shares key takeaways from the Global Academy of Women’s Cancer (GAWC) Meeting 2026.

In this insight, Dr. Almoufti reflects on the morning sessions focused on the complex management of locally advanced and metastatic breast cancer, specifically addressing ER-positive and HER2-negative disease.

🔍 Key Session Observations:
• Academic Excellence: Engagement with esteemed international faculty including Prof. Nadia Harbeck, Prof. Kuemmel (Germany), and Prof. Peter Schmid (UK).
• Clinical Application: In-depth panel discussions regarding diverse patient cases and evolving treatment protocols.
• Global Synergy: The importance of multidisciplinary dialogue in refining oncology standards of care.

The GAWC remains committed to fostering high-level scientific exchange to advance the global landscape of women’s cancer treatment.

Follow us for more updates from .
📍 Istanbul, Turkey

23/02/2026

We are honored to feature Prof. Dr. Humaid Al Shamsi (.humaidalshamsi) —Professor of Oncology at Burjeel Cancer Institute ()and President of the Emirates Oncology Society (.uae.official)—as part of our GAWC Congress Highlights series from Istanbul 2026. 🇹🇷

In this session, Prof. Al Shamsi provides expert insights into the evolving landscape of breast cancer care, specifically focusing on “The Latest Advancements in the Management of Early and Advanced Breast Cancer.”

🔬 Key Themes & Clinical Perspectives:
• Global Collaboration: Evaluating the latest therapeutic breakthroughs alongside international experts to establish a unified approach to oncology.
• Complex Case Analysis: Addressing the nuances of high-difficulty clinical cases to refine decision-making in both early and metastatic settings.
• Guideline Integration: Determining the most effective strategies for incorporating current clinical evidence and international guidelines into daily practice to optimize patient outcomes.

EmiratesOncologySociety

16/02/2026

GAWC Congress Highlights: Advanced Perspectives on Metastatic Disease

In this session, Prof. Dr. Al Nouri provides a high-level synthesis of the latest clinical data regarding ER-positive/HER2-negative metastatic breast cancer, specifically addressing the evolving landscape of second-line treatment strategies.

🧬 Clinical Focus Areas:
• Data Integration: A comprehensive review of the practice-changing data presented at ASCO, ESMO, and SABCS 2025.
• Treatment Sequencing: Addressing the critical “next steps” for patients who show progression following initial therapies.
• Precision Therapeutics: Evaluating the role of oral SERDs and targeted agents for patients with specific genomic alterations, including ESR1 and PIK3CA
• Optimizing Outcomes: Implementing evidence-based sequencing to improve long-term management of metastatic disease.

The GAWC remains committed to bridging the gap between global research and clinical practice to enhance the standard of care for women worldwide.

04/02/2026

Thank you, Istanbul 🇹🇷

GAWC 2026 brought together an outstanding international faculty and a highly engaged community for two days of focused, case-driven discussion in breast cancer.

From endocrine strategies in HR+ disease to ADCs, immunotherapy, HER2-positive and triple-negative breast cancer, early-stage decision-making, and what’s coming next in 2026 — the programme was built around real-world challenges, clinical relevance, and open scientific exchange between the faculty and the participants.

A sincere thank you to our scientific leaders, faculty, chairs, participants, and industry partners for making this edition truly impactful.

🎥 Stay connected: expert video insights, highlights, and upcoming GAWC news will be shared soon across our channels.

20/01/2026

Letzte Chance zur Teilnahme am führenden Brustkrebs-Webinar 2026.

In nur knapp zwei Stunden startet das Webinar der Global Academy of Women’s Cancer mit den wichtigsten klinischen Erkenntnissen aus ESMO, ASCO und SABCS 2025.

Führende Experten und Expertinnen fassen die entscheidenden Studien zusammen und ordnen sie praxisnah für Ihre tägliche Arbeit ein.

In zwei fokussierten Sessions erhalten Sie einen klaren, evidenzbasierten Überblick über aktuelle Entwicklungen beim frühen und fortgeschrittenen Mammakarzinom.

📌 Frühes Mammakarzinom mit Prof. Dr. Nadia Harbeck aus München
📌 Fortgeschrittenes Mammakarzinom mit Prof. Dr. Peter Schmid aus London

🕡 Start: Heute | 20.01.2026 von 18:30 bis 20:30 Uhr

🌐 Veranstalter:

Jetzt noch schnell online anmelden: https://lnkd.in/dehn9Gzj

20/01/2026

Letzte Chance zur Teilnahme am führenden Brustkrebs-Webinar 2026.
In nur knapp drei Stunden startet das Webinar der Global Academy of Women’s Cancer mit den wichtigsten klinischen Erkenntnissen aus ESMO, ASCO und SABCS 2025. Führende Experten und Expertinnen fassen die entscheidenden Studien zusammen und ordnen sie praxisnah für Ihre tägliche Arbeit ein.

In zwei fokussierten Sessions erhalten Sie einen klaren, evidenzbasierten Überblick über aktuelle Entwicklungen beim frühen und fortgeschrittenen Mammakarzinom.

📌 Frühes Mammakarzinom mit Prof. Dr. Nadia Harbeck aus München
📌 Fortgeschrittenes Mammakarzinom mit Prof. Dr. Peter Schmid aus London

🕡 Start: Heute in 4 Stunden | 20.01.2026 von 18:30 bis 20:30 Uhr

🌐 Veranstalter: MedConcept mbH

Jetzt noch schnell online anmelden: https://medconcept.swoogo.com/GAWC_Webinar_2026

16/01/2026

In this highlight, Prof. Dr. Hope S. Rugo, Director of Breast Oncology and the Women’s Cancers Program at City of Hope, discusses the latest breakthroughs in Antibody Drug Conjugates (ADCs).

Prof. Rugo dives into:
🧬 The newest data presented at ASCO 2025 and its application in real-world metastatic patient cases.

🧪 Managing the toxicity of ADCs proactively through prophylactic approaches and dose adjustments.

🫁 Specific insights on managing interstitial lung disease with Trastuzumab Deruxtecan.

🚀 The future of ADCs, including active trials in triple-negative and HER2-positive disease, and moving these treatments into early-stage settings.

The discussions at GAWC 2025 have been robust and forward-thinking, bridging the gap between clinical data and patient care.

Stay tuned for more highlights!

09/01/2026

In this session, Prof. Dr. Fotopoulou discusses the evolving landscape of surgical intervention for both advanced and relapsed ovarian cancer, focusing on two landmark data sets:

• The TRUST Study: A deep dive into the implications for clinical practice, emphasizing that the cornerstone of patient care remains high-maximal effort surgery performed within expert, accredited centers.

• SuROC-CON Data: An analysis of a significant multi-center study involving over 3,000 patients across five international centers (including MSK, Mayo Clinic, and Imperial). The data provides a “treasure” of information regarding prognostic factors and the surgical benefits across various histologies.

The discussion also explores how the surgical landscape is evolving in the era of PARP inhibitors, with full data from the SuROC-CON study expected to be published soon.

As we look forward to our next Meeting in Istanbul (January 30-31, 2026), we invite you to watch the full reel for these essential updates.

Stay tuned for more insights.

Learn more about GAWC: 🔗 global-academy-of-womens-cancer.org [LINK IN BIO]

Adresse

Friedenstraße 58
Neuenhagen
15366

Telefon

+4933424268913

Webseite

https://global-academy-of-womens-cancer.org/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Global Academy of Women's Cancer erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.